PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

No treatment effect observed in this patient population; substantial improvement in 6-minute walk test seen in both placebo and active groups Study adds to growing body of data supporting strong safety and tolerability profile of LYT-100 (deupirfenidone) Company will drive LYT-100 forward in other indications, with a focus on IPF where human clinical efficacy has … [Read more…]

Children’s Hospital Los Angeles: The Best Care for Kids in California and the West Coast

U.S. News & World Report’s annual hospital survey again ranks Children’s Hospital Los Angeles among the top 10 pediatric hospitals in the nation LOS ANGELES–(BUSINESS WIRE)–#childrenshealth–Children’s Hospital Los Angeles (CHLA) continues its streak of being California’s top hospital for pediatric care and specialty services, according to U.S. News & World Report’s 2022-23 Best Children’s Hospitals … [Read more…]

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

– First and Only FDA-approved Treatment Demonstrating Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – AMVUTTRA Met Primary and All Secondary Endpoints, with Significant Improvement in Polyneuropathy, Quality of Life and Gait Speed Relative to External Placebo – – Company Expects to Launch in Early July, with Value-Based Agreements to … [Read more…]

Rockley Photonics Set to Join Russell 3000® Index

OXFORD, England & PASADENA, Calif.–(BUSINESS WIRE)–$RKLY #RKLY–Rockley Photonics Holdings Limited (NYSE: RKLY), a global leader in photonics-based health monitoring and communications solutions, announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022, according … [Read more…]

Persad Center Announces Date for 2022 Annual Fundraising Gala, Art for Change; Launches Pilot Program to Support Artists

Funds Raised Will Support Mental Health Services for Pittsburgh’s LGBTQ+ Community PITTSBURGH–(BUSINESS WIRE)–Persad Center is hosting “Art for Change 2022” on Friday, September 9 at Stage AE on the North Shore. The event, Persad’s 35th Annual, is one of the region’s most significant art auctions. Proceeds support Persad Center’s mission of providing mental health services … [Read more…]

Humana to Donate Downtown Louisville Office Building to UofL

LOUISVILLE, Ky.–(BUSINESS WIRE)–Humana Inc. (NYSE: HUM) today announced that it will donate an office building in Downtown Louisville to the University of Louisville (UofL) in support of the activities of UofL’s Health Equity Innovation Hub. The 8-story building, located at 515 W. Market Street, was recently vacated by Humana and contains approximately 130,000 square feet … [Read more…]

Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual

NEW YORK–(BUSINESS WIRE)–Accolade Health, Inc. (“Accolade”) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, announced that on June 8, 2022 the Compensation Committee of Accolade’s Board of Directors approved the grant of inducement restricted stock unit awards covering 992,382 Class A shares of Accolade’s common stock to 29 new … [Read more…]

CONMED Completes Acquisition of In2Bones Global, Inc.

LARGO, Fla.–(BUSINESS WIRE)–CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced acquisition of privately-held In2Bones Global Inc. Headquartered in Memphis, Tennessee, In2Bones is a global developer, manufacturer, and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. … [Read more…]

Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47

NEW YORK & BOSTON & WILMINGTON, Del.–(BUSINESS WIRE)–Pfizer Inc. (NASDAQ:PFE), MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ:MOR), and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration and supply agreement to investigate the immunotherapeutic combination of Pfizer’s TTI-622, a novel SIRPα-Fc fusion protein, and Monjuvi® (tafasitamab-cxix) plus lenalidomide in patients … [Read more…]

Outset Medical Announces Shipment Hold on New Tablo Systems for Home Use Pending FDA Review and Clearance of Recent 510(K) Submission

Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST SAN JOSE, Calif.–(BUSINESS WIRE)–Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “company”) today announced it has implemented a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending the Food and Drug Administration’s (FDA) review and clearance of a 510(k) the … [Read more…]